Highlights of This Issue 4741

SPECIAL FEATURES

CCR 20th Anniversary Commentary

4743 CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?
Isabelle Gingras, Christine Desmedt, Michail Ignatiadis, and Christos Sotiriou

CCR Translations

4747 Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations
Rani E. George
See related article, p. 4913

4750 Less Can Be More for Gene Dose and Drug Sensitivity
Susanne A. Gatz and Janet M. Shipley
See related article, p. 4947

CCR New Strategies

4753 New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype
Jamie Lim, Neal M. Poulin, and Torsten O. Nielsen

CCR Perspectives in Drug Approval

4760 FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver, Laleh Amiri-Kordestani, Rosane Charlab, Wei Chen, Todd Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, Joyce Cich, Xiao Hong Chen, Minerva Hughes, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Paul G. Kluetz, Geoffrey Kim, Amna Ibrahim, Richard Pazdur, and Patricia Cortazar

CCR Drug Updates

4767 Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach, Philippe Moreau, Jesús F. San-Miguel, and Paul G. Richardson

Molecular Pathways

4774 Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
Leticia Corrales and Thomas F. Gajewski

4780 Molecular Pathways: Targeting ATR in Cancer Therapy
Larry M. Karnitz and Lee Zou

Review

4786 Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
Michail Ignatiadis, Mark Lee, and Stefanie S. Jeffrey

CANCER THERAPY: CLINICAL

4801 Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqiu Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Gobly C. George, Lucy Xu, Robert Shumaker, Min Ren, Jennifer Mink, Cynthia Bedell, Corina Andrensen, Pallavi Sachdev, James P. O’Brien, and John Nemunaitis

PERSONALIZED MEDICINE AND IMAGING

4811 SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo, Carlos Plaza, Monica Musteanu, Peter Illei, Carrie B. Brachmann, Carla Heise, Daniel Pierce, Pedro P. Lopez-Casas, Camino Menendez, Josep Taberner, Alfredo Romano, Xinyu Wei, Fernando Lopez-Rios, and Daniel D. Von Hoff
## CANCER THERAPY: PRECLINICAL

### 4819 Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors

Shengjun Lu, Jinyu Zhang, Dai Liu, Guangfu Li, Kevin F. Staveley-O’Carroll, Zihai Li, and Jennifer D. Wu

### 4831 Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins

Noriaki Tanaka, Ameeta A. Patel, Jiping Wang, Mitchell J. Frederick, Nene N. Kalu, Mei Zhao, Alison L. Fitzgerald, Tong-xin Xie, Natalie L. Silver, Carlos Caulin, Ge Zhou, Heath D. Skinner, Faye M. Johnson, Jeffrey N. Myers, and Abdullah A. Osman

### 4845 siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer

Yoshiaki Yamamoto, Paulo J.C. Lin, Eliana Beraldi, Fan Zhang, Yoshihisa Kawai, Jeffrey Leon, Hidehisa Katsumi, Ladan Fazli, Robert Fraser, Pieter R. Cullis, and Martin Gleave

### 4856 Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model

Ruben Bill, Erneata Fagiani, Adrian Zumsteg, Helena Antoniadis, David Johansson, Simon Haefliger, Imke Albrecht, Frank Hilberg, and Gerhard Christofori

## BIOLOGY OF HUMAN TUMORS

### 4868 Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3–FOXO1-Positive Alveolar Rhabdomyosarcoma

Julie J.C. Kephart, Rosanne G.J. Tiller, Lisa E.S. Crose, Katherine K. Sleemmons, Po-Han Chen, Ashley R. Hinson, Rex C. Bentley, Jen-Tsan Ashley Chi, and Corinne M. Linardic

### 4879 LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival

Sofía Torres, Irene García-Palmero, Mercedes Herrera, Rubén A. Bartolome, Cristina Peña, M. Jesús Fernandez-Acero, Guillermo Padilla, Alberto Peláez-García, María Lopez-Luendo, Rufo Rodríguez-Merlo, Antonio García de Herreros, Félix Bonilla, and J. Ignacio Casal

### 4881 Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis

Angela Bellini, Virginie Bernard, Quentin Leroy, Thomas Rio Frio, Gaelle Pierré, Valérie Combaret, Eve Lapouble, Nathalie Clement, Herve Rubie, Estelle Thebaud, Pascal Chastagner, Anne Sophie Defachelles, Christophe Bergeron, Nimrod Buchbinder, Sophie Taque, Anne Auvignon, Dominique Valeau-Couanet, Jean Michon, Isabelle Janoueix-Lerosey, Olivier Delattre, and Gudrun Schleiermacher

### 4892 MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16

Chao Cai, Qing-Biao Chen, Zhao-Dong Han, Yan-Qiong Zhang, Hui-Chan He, Jia-Hong Chen, Yan-Ru Chen, Sheng-Bang Yang, Yong-Ding Wu, Yan-Ru Zeng, Guo-Qiang Qin, Yu-Xiang Liang, Qi-Shan Dai, Fu-Neng Jiang, Shu-lin Wu, Guo-Hua Zeng, Wei-De Zhong, and Chin-Lee Wu

### 4903 Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4947</td>
<td>CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma</td>
<td>Mary E. Olanich, Wenyue Sun, Stephen M. Hewitt, Zied Abdullaev, Svetlana D. Pack, and Frederic G. Barr</td>
</tr>
<tr>
<td>4975</td>
<td>AMER1 Is a Frequently Mutated Gene in Colorectal Cancer—Letter</td>
<td>Pilar Mur, Gemma Aiza, Rebeca Sanz-Pamplona, Sara Gonzalez, Matilde Navarro, Victor Moreno, Gabriel Capella, and Laura Valle</td>
</tr>
</tbody>
</table>

**LETTER TO THE EDITOR**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4975</td>
<td>AMER1 Is a Frequently Mutated Gene in Colorectal Cancer—Letter</td>
<td>Pilar Mur, Gemma Aiza, Rebeca Sanz-Pamplona, Sara Gonzalez, Matilde Navarro, Victor Moreno, Gabriel Capella, and Laura Valle</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

The cover shows the migratory ability of DU145 prostate cancer cell lines transfected with miRNA negative control lentiviral vector (miR-NC) by wound healing. For details, see the article by Cai and colleagues on page 4922 of this issue.